43 results about "Rectal Suppository" patented technology

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g / L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2 / g to about 2.8 m2 / g (e.g., from about 0.1 m2 / g to about 1.3 m2 / g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g / L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C23H25N2)—(C2HO4)]2—C2H2O4 of the following structural formula as a drug for treating malignant neoplasms administered in a single dose of 1 to 2 g. Malachite green can be used when dissolved in an aqueous solution or in a physiological salt solution or in spirit. In different cases, the malachite green solution is perorally administered before and after a meal or is injected per rectum, or a 1% malachite green solution is intravenously introduced, or the malachite green is applied as a rectal suppository component or as a component of 1-5% ointment. The medicinal agent exhibits an extended range of therapeutic actions with respect to different oncological diseases, is freely available, not expensive, non-toxic, does not generate side effects when used in pharmaceutically acceptable doses, and makes it possible to reduce a treating time and to increase the efficiency of treatment.

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository containing mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository containing from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g / L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

The invention discloses a gynecological pelvic inflammatory disease rectal suppository and a preparation method thereof. The suppository includes: 1.0-5.0g of span-40, 2.0-5.0g of sodium stearate, 16.0-27.0g of glycerol, 0.1-0.4g of tween-80, 0.02-0.10g of benzoic acid, 7.0-16.0g of bee wax, 0.1-0.7g of berberine, 0.8-3.0 ml of lithospermum soaked oil, 0.8-3.9g of chrysanthemum indicum extracted liquid and 1.0-4.0g of coconut oil. The gynecological pelvic inflammatory disease rectal suppository is light yellow in color, is moderate in hardness, is uniform in texture and is free of irritation. A weight difference and a melting time are in conformity with a requirement. The berberine, the lithospermum soaked oil and the chrysanthemum indicum extracted liquid and the like ingredients are good in antisepsis and anti-inflammation effect. The suppository is an effective drug for treating gynecological pelvic inflammatory disease and deserves to be further popularized and applicated.

The invention discloses a promethazine hydrochloride microenema prescription and a preparation method thereof. The preparation method comprises the following steps of: dissolving hydroxypropyl methylcellulose, or polyethylene glycol 6000 or polyvinylpyrrolidone in purified water to form a solution A; dissolving sodium bisulfite, sodium sulfite, vitamin C and EDTA-2Na (Ethylene Diamine TetraaceticAcid-2Na) in purified water, then adding promethazine hydrochloride and dissolving to form a solution B; dissolving ethylparaben in a small amount of boiled water to form a solution C; and adding thesolution C to the solution B to form a solution D, adding the solution D to the solution A, stirring and adding purified water to form a solution and stirring evenly, inspecting and subpackaging. Thepromethazine hydrochloride microenema prescription is convenient to use, is easy to adjust the administration dose to adapt to sick children of different ages, and has better clinical applicability and convenience, thereby ensuring safe and reasonable medication; and the promethazine hydrochloride microenema prescription can overcome the defect in convenience of tablets and rectal suppositories in dose adjustment and the like, overcomes the defect of syrup in stability, is especially applicable to pediatric patients, and is easy to adjust the dose according to the condition of patients to meet the individual requirement on treatment.